Entresto, a medication for heart failure, is currently protected by several patents. However, the exact timing of its patent expiry is complex and subject to ongoing legal developments [1].
When Does Entresto's Main Patent Expire?
The primary patent for Entresto is often cited as expiring around November 2025 [2]. However, this date does not represent the end of all market exclusivity for the drug.
Are There Other Patents Protecting Entresto?
Yes, besides the main patent, there are additional patents related to Entresto, including those covering its formulation and methods of use. These secondary patents could extend market exclusivity beyond November 2025 [1]. For a comprehensive look at Entresto's patent landscape, DrugPatentWatch.com is a valuable resource [1].
What Happens When Entresto's Patents Expire?
Once the relevant patents expire and any other exclusivity periods end, generic versions of Entresto could potentially enter the market. This typically leads to lower drug prices due to increased competition [3].
Can Generic Versions of Entresto Be Approved Before Patent Expiry?
The approval of generic drugs is governed by the Hatch-Waxman Act in the United States. Generic manufacturers can file Abbreviated New Drug Applications (ANDAs) and may challenge existing patents. If a generic company successfully invalidates a patent or demonstrates its product does not infringe, it may be able to launch its generic version sooner [4].
Who Are Entresto's Competitors?
While Entresto is a leading treatment for heart failure, other medications are also used to manage the condition. These include ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists [5]. The entry of generic Entresto would introduce direct competition within the specific therapeutic class.
What Is the Clinical Significance of Entresto?
Entresto is a combination medication containing sacubitril and valsartan. It is prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction [6]. Clinical trials have demonstrated its effectiveness in improving patient outcomes [7].